Doubling the Semaglutide Dose Improves Weight Loss
May 25, 2021
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Emmanuel Obi, PharmD Candidate, Lake Erie College of Osteopathic Medicine (LECOM), School of Pharmacy, Bradenton, Florida
Lifestyle management and intervention alongside a once-weekly semaglutide dose of 2.4 mg (doubling the standard dose of 1.0) can lead to improved weight loss for patients with overweight or obesity.
Obesity is a risk factor in many health conditions and can lead to hypertension, dyslipidemia, insulin resistance, type 2 diabetes (T2D), liver disease, and cardiovascular disease (CVD). It is a well-known health challenge globally. Experts have always recommended lifestyle changes like diet and exercise and adjunct pharmacologic approaches to help combat obesity. However, lifestyle interventions have not effectively sustained weight loss over a more extended period for most patients. Also, pharmacologic intervention is limited because of cost, safety concerns, and low efficacy. Semaglutide is a glucagon-like peptide-1 (GLP-1) analog approved for treating T2D in adults and reducing cardiovascular risk for a person with T2D. It was found to also induce weight loss in persons with T2D participating in a phase 3 trial....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.